Literature DB >> 14553948

Microsatellite alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Sun Hoe Koo1, Chun Hwa Ihm, Kye Chul Kwon, Jae Sik Lee, Jong Woo Park, Jong Wan Kim.   

Abstract

A series of 20 hepatocellular carcinomas and 8 intrahepatic cholangiocarcinomas was screened from the Korean population for microsatellite alterations, including a loss of heterozygosity and replication errors using nine microsatellite markers containing several genes. The microsatellite results and our previous comparative genomic hybridization results of two tumors were compared at each locus, and the correlations between these and clinicopathologic variables were examined. The most characteristic findings were found at 13q. Replication errors were prevalent at D13S160 (13q21.2 approximately q31) and D13S292(13q12). The incidence of loss of heterozygosity, however, was higher at D13S153 (13q14.1 approximately q14.3) and D13S265(13q31 approximately q32). In contrast, there were higher deletion frequencies observed in hepatocellular carcinoma (HCC) and higher amplification frequencies observed in intrahepatic cholangiocarcinoma at 13q in our previous comparative genomic hybridization (CGH) study. Higher frequencies of replication errors were observed at D16S408 (13q12 approximately q21) and D16S504(13q23 approximately q24) in the HCC. This study found that significant differences in the patterns of genetic instability of microsatellites were dependent on the chromosomal loci. It is believed that certain genes at altered CGH regions, which are relevant to the development and/or progression of these cancers, are activated by different mutation mechanisms.

Entities:  

Mesh:

Year:  2003        PMID: 14553948     DOI: 10.1016/s0165-4608(03)00133-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma.

Authors:  Temduang Limpaiboon; Sumonta Tapdara; Patcharee Jearanaikoon; Banchob Sripa; Vajarabhongsa Bhudhisawasdi
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

2.  Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma.

Authors:  Jongkonnee Thanasai; Temduang Limpaiboon; Patcharee Jearanaikoon; Vajarabhongsa Bhudhisawasdi; Narong Khuntikeo; Banchob Sripa; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

3.  Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?

Authors:  Mia Kumar; Xuelian Zhao; Xin Wei Wang
Journal:  Cell Biosci       Date:  2011-01-24       Impact factor: 7.133

4.  Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.

Authors:  Elena Czink; Matthias Kloor; Benjamin Goeppert; Stefan Fröhling; Sebastian Uhrig; Tim F Weber; Jörn Meinel; Christian Sutter; Karl Heinz Weiss; Peter Schirmacher; Magnus von Knebel Doeberitz; Dirk Jäger; Christoph Springfeld
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-09-01

5.  Low frequency of mismatch repair deficiency in gallbladder cancer.

Authors:  Benjamin Goeppert; Stephanie Roessler; Marcus Renner; Moritz Loeffler; Stephan Singer; Melina Rausch; Thomas Albrecht; Arianeb Mehrabi; Monika Nadja Vogel; Anita Pathil; Elena Czink; Bruno Köhler; Christoph Springfeld; Christian Rupp; Karl Heinz Weiss; Peter Schirmacher; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Diagn Pathol       Date:  2019-05-08       Impact factor: 2.644

6.  Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.

Authors:  Benjamin Goeppert; Stephanie Roessler; Marcus Renner; Stephan Singer; Arianeb Mehrabi; Monika Nadja Vogel; Anita Pathil; Elena Czink; Bruno Köhler; Christoph Springfeld; Jan Pfeiffenberger; Christian Rupp; Karl Heinz Weiss; Peter Schirmacher; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Br J Cancer       Date:  2018-10-31       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.